30
Participants
Start Date
April 27, 2022
Primary Completion Date
August 7, 2023
Study Completion Date
January 26, 2024
Daxdilimab
Daxdilimab will be administered subcutaneously as two injections for each dose.
ForCare Clinical Research, Tampa
DS Research, Louisville
Burke Pharmaceutical Research, Hot Springs
Progressive Clinical Research, P.A., San Antonio
First OC Dermatology Research, Inc., Fountain Valley
Dermatology Specialists of Spokane, Spokane
Enverus Medical Research, Surrey
Dr Dusan Sajic Medicine Professional Corporation, Guelph
Lynderm Research Inc., Markham
The Centre for Clinical Trials, Oakville
SKiN Centre for Dermatology, Peterborough
Innovaderm Research, Montreal
Centre de Recherche Saint-Louis (Quebec), Québec
Lead Sponsor
Amgen
INDUSTRY